FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> hepatitis B

Vaccination campaigns beat back viral hepatitis


The most serious types of viral hepatitis show signs of a steady retreat, beaten back by years of persistent vaccination campaigns in the U.S. Experts at the CDC say that there's been a decrease of hepatitis A infections in adults, a big drop in hepatitis B infections in people aged 6 to 39 and a slide in hepatitis C cases in the group considered most at risk.

Decades of vaccination campaigns against hepatitis A and B appear to have worked on that front, while the CDC says that hepatitis C cases may be falling as a result of a campaign to warn people away from the kind of risky behavior that spreads the virus.

Hepatitis B and C can both trigger chronic infections leading to liver disease and cancer. And HealthDay also notes that hepatitis C is the most commonly seen blood borne infection in the country. HCV is also a big target for drug developers--like Vertex--interested in grabbing a share of a huge market. And like HIV, developers are targeting a new generation of combination therapies.

"It really became clear early on that these hepatitis C agents couldn't really be given [as single agents] because of the virus's ability to develop resistance," Vertex CMO Bob Kauffman recently told Xconomy. Other drug projects are underway at Abbott Laboratories, Merck, Anadys and Gilead.

- here's the story from HealthDay

Related Articles:
Mouse/human chimera will aid hepatitis research
Stanford scientists identify a new class of hep C drugs
UCLA team heralds groundbreaking hep C drug discovery

Bookmark and Share
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about hepatitis B  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.